Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Do you resume RT for LS-SCLC after a prolonged break?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Quillen VA Medical Center

Compressing TRT to 3 or 4 weeks minimizes the chance of breaks more prevalent with 6-7 week plans. You cannot make up for lost effectiveness by resuming after break for whatever reason. I do not break for counts.

Would you consider maintenance immunotherapy after cisplatin-gemcitabine chemotherapy and chemoRT for stage 3 bladder cancer in a patient declining cystectomy or who is a poor surgical candidate?

2
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Washington School of Medicine

Great question and relevant clinical scenario. We need a clinical trial in this setting, the INSPIRE (EA8185, PI: Dr. @Dr. First Last) is an ideal trial to enroll. In the meantime, would not add "consolidation/maintenance" ICI in the absence of data in this particular setting.

How would you approach consolidative rectal irradiation for a patient with liver-confined metastatic rectal adenocarcinoma, who has sustained a near-CR after CAPEOX, capecitabine, and ongoing bevacizumab?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan-Kettering Cancer Center

Yes, they are curable with liver directed therapy, I would treat with curative intent non-operative management. If they are not curable, would not treat unless until progression.

What staff members would you recommend to start a Lu-177 PSMA therapy program?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Abramson Cancer Center, University of Pennsylvania

The manuscripts below are thorough and provide the information needed.Local context matters and the setting - Nuc med vs in rad onc vs other, as well as the resources available in your clinical setting, and finally any extended services you might perform (e.g., dosimetry) you might need more personn...

When treating sinonasal undifferentiated carcinoma (SNUC) with induction chemotherapy followed by definitive chemoradiation, do you include the entire pre-chemo volume in your high-dose CTV?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Florida

Yes

What treatment would you recommend for DCIS incidentally found in pathologic specimen following breast reduction surgery?

3
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Miami Miller School of Medicine

This is a challenging situation that can be seen in spite of evaluation prior to definitive procedure. I would agree with an MRI after the patient heals to look for any obvious residual disease. In the absence of a completion mastectomy which is usually unlikely, I would favor a course of whole brea...

Are there any potential benefits to irradiating the partial breast with an MR-linac over conventional linac?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Allegheny Health Network, Pittsburgh

The group at WashU has done a great job publishing on this topic (Price et al., PMID 34624406).At this time, I don't think we can say there is a clear benefit to MR linac over conventional CBCT when it comes to cancer control or toxicity, though there may be dosimetric benefits (that could translate...

What is your approach to adjuvant vaginal cuff radiation in patients with prior definitive pelvic radiation therapy?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I do take the previous dose into account. Sometimes use a multichannel cylinder and try to control the rectum and bladder dose. Also, prescribe lower end of acceptable dose schedule like 6 Gy x 5 to surface or 4 Gy x 6 to surface.

In a patient with rectal adenocarcinoma and involved gluteal lymph nodes, what would your elective lymph node volume include?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Washington University School of Medicine

I think the most important issue to address in this case, is how disease accessed the subgluteal space. I had a case like this in a patient with a very deeply invasive disease. During chemoRT, the patient required a diverting ileostomy after they developed a recto-cutaneous fistula due to rapid tumo...

How would you sequence treatment of a synchronous IC1 high-grade serous ovarian cancer and cT3N1 rectal cancer?